Pentoxifylline and reduced doses of steroids combination in pulmonary sarcoidosis

H. Baradzina, I. Kotovich, A. Tahanovich (Minsk, Belarus)

Source: Annual Congress 2007 - Considerations in the therapeutic approach of interstitial lung disease: oxidative stress and inflammation
Disease area: Interstitial lung diseases

Congress or journal article abstract

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
H. Baradzina, I. Kotovich, A. Tahanovich (Minsk, Belarus). Pentoxifylline and reduced doses of steroids combination in pulmonary sarcoidosis. Eur Respir J 2007; 30: Suppl. 51, 771

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Combination of pentoxifylline and steroids in sarcoidosis treatment
Source: Eur Respir J 2005; 26: Suppl. 49, 269s
Year: 2005

Pentoxifylline in treatment of pulmonary sarcoidosis
Source: Eur Respir J 2002; 20: Suppl. 38, 433s
Year: 2002

Azathioprine and low-dose prednisone in chronic pulmonary sarcoidosis
Source: Eur Respir J 2005; 26: Suppl. 49, 268s
Year: 2005

Comparison of prednisolone and budesonide in the treatment of pulmonary sarcoidosis
Source: Eur Respir J 2005; 26: Suppl. 49, 80s
Year: 2005

Combination treatment with nintedanib and prednisolone for patients with idiopathic pulmonary fibrosis
Source: International Congress 2018 – Management of idiopathic interstitial pneumonias: established and new treatments
Year: 2018

Idiopathic pulmonary fibrosis: efficacy of complex immunosuppressive therapy by cyclophosphamide and corticosteroids
Source: Annual Congress 2009 - Various backgrounds in diffuse parenchymal lung disease
Year: 2009

Low dose intravenous iloprost therapy in idiopathic pulmonary arterial hypertension
Source: Eur Respir J 2006; 28: Suppl. 50, 426s
Year: 2006

Long-term treatment of pulmonary hypertension with aerosolized iloprost
Source: Eur Respir J 2001; 17: 8-13
Year: 2001



Exacerbations of idiopathic pulmonary fibrosis treated with corticosteroids and cyclophosphamide pulses
Source: Eur Respir J 2011; 38: 1487-1489
Year: 2011


Efficiency of pentoxifylline different doses in sarcoidosis treatment
Source: Annual Congress 2008 - Clinical aspects in the management of sarcoidosis
Year: 2008

Inhaled iloprost plus oral sildenafil in patients with pulmonary hypertension
Source: Eur Respir J 2001; 18: Suppl. 33, 324s
Year: 2001

Combination therapy in severe pulmonary hypertension with bosentan and treprostinil: successful switch from subcutaneous to intravenous application
Source: Eur Respir J 2006; 28: Suppl. 50, 384s
Year: 2006

Efficacy and toxicity of azathioprine plus corticosteroids in 32 patients with chronic persistent sarcoidosis
Source: Eur Respir J 2004; 24: Suppl. 48, 712s
Year: 2004

Effects of prednisolone and imatinib mesylate on inflammation and fibrosis in amiodarone-induced pulmonary toxicity in rats
Source: Annual Congress 2010 - Regulation of airway pharmacology
Year: 2010


The evaluatuion of effectiveness of small doses of pentoxifylline in combination with tocopherol acetate in intrathoracic sarcoidosis
Source: Eur Respir J 2004; 24: Suppl. 48, 669s
Year: 2004

Intravenous pulse doses of high-dose corticosteroid and cyclophosphamide in acute exacerbation of idiopathic pulmonary fibrosis
Source: International Congress 2015 – IPF: from bench to bedside
Year: 2015

Long-term response to prednisone in newly treated patients with pulmonary sarcoidosis
Source: Virtual Congress 2021 – Better understanding of sarcoidosis: new keys
Year: 2021



Colchicine, prednisone versus no therapy in idiopathic pulmonary fibosis
Source: Eur Respir J 2006; 28: Suppl. 50, 744s
Year: 2006

Addition of sildenafil to bosentan monotherapy in pulmonary arterial hypertension
Source: Eur Respir J 2007; 29: 469-475
Year: 2007



Comparative analysis of the efficacy of glucocorticosteroids and antimetabolite drugs in treatment of patients with pulmonary sarcoidosis
Source: International Congress 2019 – Granulomatous disorders: pathogenesis, epidemiology and clinical issues
Year: 2019